Marisa Wexler, MS,  senior science writer—

Mabwell’s experimental therapy 9MW1911 may reduce the frequency of moderate to severe exacerbations in people with chronic obstructive pulmonary disease (COPD), according to data from a completed Phase 2a clinical trial. The results were announced in a press release from Mabwell. The company is now conducting a…

The American Lung Association Research Institute is investing $22 million to advance research and support care for lung disease, including chronic obstructive pulmonary disease (COPD). “Research is the foundation for every breakthrough that improves lung health and saves lives,” said Harold Wimmer, president and CEO of the…

A Phase 3 clinical trial testing AstraZeneca’s injection therapy benralizumab as a potential treatment for chronic obstructive pulmonary disease (COPD) has failed to meet its main goal of showing the therapy’s superiority over a placebo in terms of the ability to reduce the rate of moderate or…

Genentech has announced mixed top-line results from two global clinical trials testing its treatment candidate astegolimab in people with moderate to very severe chronic obstructive pulmonary disease (COPD). Both one-year trials aimed to demonstrate that the therapy was superior to a placebo at reducing the annual rate of…

The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain people with chronic obstructive pulmonary disease (COPD). The treatment, from GSK, is specifically indicated for adults with COPD whose disease is not adequately controlled with other therapies and who have…

The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly known as RSV — for adults as young as 18 with chronic obstructive pulmonary disease (COPD) or other conditions that increase the risk of…

The U.S. Food and Drug Administration (FDA) has granted breakthrough designation to tezepelumab, an approved therapy for severe asthma, as an add-on maintenance treatment for moderate to very severe chronic obstructive pulmonary disease (COPD) marked by an eosinophilic profile. An eosinophilic profile refers to high blood levels of eosinophils,…

People who get more vitamin E from their diet may be less likely to develop chronic obstructive pulmonary disease (COPD), an analysis suggests. Findings indicate that vitamin E supplementation may help in preventing COPD, but more research is needed to confirm this, researchers note. The study “…

The U.S. Food and Drug Administration (FDA) has approved Verona Pharma’s ensifentrine as an inhaled maintenance therapy for adults with chronic obstructive pulmonary disease (COPD). The decision makes ensifentrine — to be marketed under the brand name Ohtuvayre — the first therapy with a new mechanism of action…

A new campaign will highlight the ways certain jobs, including those related to mining, agriculture, and manufacturing, can increase the risk of developing chronic obstructive pulmonary disease (COPD). Long-term exposure to dust, chemicals, fumes, and vapors in the workplace may all lead to COPD, said the American Lung…